Innate Pharma H1 EPS $0.02 Down From $0.09 YoY, Sales $43.81M Down From $49.88M YoY
Portfolio Pulse from Benzinga Newsdesk
Innate Pharma (NASDAQ:IPHA) reported a 77.78% decrease in quarterly earnings YoY, with EPS of $0.02, down from $0.09. Sales also decreased by 12.17% to $43.81 million. The company's cash position as of June 30, 2023, was €124.7 million, with an anticipated cash runway into H2 2025.
September 14, 2023 | 5:26 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Innate Pharma reported a significant decrease in earnings and sales YoY. However, the company maintains a strong cash position.
The significant decrease in earnings and sales YoY could negatively impact the company's stock price in the short term. However, the strong cash position could provide some stability.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100